Table 1. Patients characteristics.

	Group A (placebo)	Group B (dutasteride)	p value
Patients, n	190	190
Age, y	60 (53-78)	62 (50-80)	0.49
PSA, (ng/ml) ± SD	5.18 ± 4.09	2.79 ± 2.22	< .05
TT, (ng/dl) ± SD	599 ± 244	546 ± 313	0.09
DHT, (ng/dl) ± SD	51 ± 29	6 ± 5	< .05
Prostate Volume, (ml) ± SD	71.55 ± 35.86	68.34 ± 43.37	0.34
Cut volume, (ml) ± SD	31.58 ± 9.87	32.15 ± 8.36	0.58
Enucleation rate (g/min)	1.32 ± 0.34	1.09 ± 0.31	< .05
Morcellation rate (g/min)	5.65 ± 1.98	5.34 ± 1.91	0.44
Operating time, min	69 ± 31	76 ± 36	0.19
Incidental prostate cancer	15	13

PSA: prostate specific antigen; TT: total testosterone; DHT: dihydrotestosterone; SD: standard deviation.